Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Depreciation & Amortization (CF): 2019-2025

Historic Depreciation & Amortization (CF) for Eton Pharmaceuticals (ETON) over the last 7 years, with Sep 2025 value amounting to $1.0 million.

  • Eton Pharmaceuticals' Depreciation & Amortization (CF) rose 262.95% to $1.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.4 million, marking a year-over-year increase of 203.05%. This contributed to the annual value of $1.1 million for FY2024, which is 27.19% up from last year.
  • According to the latest figures from Q3 2025, Eton Pharmaceuticals' Depreciation & Amortization (CF) is $1.0 million, which was up 0.40% from $1.0 million recorded in Q2 2025.
  • Over the past 5 years, Eton Pharmaceuticals' Depreciation & Amortization (CF) peaked at $1.2 million during Q2 2022, and registered a low of $85,000 during Q2 2021.
  • Moreover, its 3-year median value for Depreciation & Amortization (CF) was $279,000 (2024), whereas its average is $461,273.
  • In the last 5 years, Eton Pharmaceuticals' Depreciation & Amortization (CF) skyrocketed by 1,277.65% in 2022 and then crashed by 85.31% in 2023.
  • Over the past 5 years, Eton Pharmaceuticals' Depreciation & Amortization (CF) (Quarterly) stood at $137,000 in 2021, then soared by 83.94% to $252,000 in 2022, then grew by 28.97% to $325,000 in 2023, then grew by 9.23% to $355,000 in 2024, then skyrocketed by 262.95% to $1.0 million in 2025.
  • Its last three reported values are $1.0 million in Q3 2025, $1.0 million for Q2 2025, and $1.0 million during Q1 2025.